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Prolactin (PRL) is a peptide hormone that is produced by
the pituitary gland and is known to regulate lactogenic
differentiation. There is a significant body of evidence
that points to autocrine production of prolactin and ac-
tivation of an autocrine/paracrine signaling pathway to
regulate cell proliferation and migration and inhibition of
cell death. This perspective highlights the recent study
in the October 1, 2012, issue ofGenes &Development by
Chen and colleagues (pp. 2154–2168) that describes a
mechanism for autocrine prolactin production and places
the finding in the context of a role for prolactin in breast
development and cancer.
Prolactin (PRL) was discovered >80 years ago and is best
known for its role in lactation (Ben-Jonathan et al. 2007).
It is a 23-kDa secreted peptide hormone that is 199 amino
acids long. Lactotrope cells in the pituitary gland synthe-
size, store, and release prolactin into the blood circulation
(Ben-Jonathan et al. 2007). The synthesis and secretion of
prolactin by the lactotrope cells is tightly regulated by
multiple factors; of particular note is the inhibitory effect
by dopaminergic neurons. Dopamine can inhibit both the
transcription of prolactin mRNA and the secretion of
prolactin protein (Ben-Jonathan and Hnasko 2001). Con-
sistent with this notion, dopamine antagonists increase
serum prolactin levels, causing hyperprolactemia (Meltzer
and Fang 1976; Wieck and Haddad 2002). Direct insights
into prolactin function are derived from studies per-
formed in rodents. Homozygous deletion of the prolactin
gene in mice results in a loss of lobular decoration in
virgin mammary glands, with no apparent changes in
development of the mammary ductal network. In addi-
tion, prolactin/ mice show defective lobuloalveolar
development during pregnancy but do not display any
other overt symptoms, thus identifying the modulation
of mammary differentiation as the primary function for
prolactin secreted by the pituitary gland (Horseman et al.
1997).
Although the pituitary gland is the major source of
prolactin synthesis, extrapituitary cells such as decidual
cells, adipocytes, T lymphocytes, mononuclear cells, and
breast cancer-derived cells (discussed below) also produce
prolactin (Ben-Jonathan et al. 1996). Unlike the lactotrope
cells in the pituitary gland that have a large capacity to
store synthesized prolactin, extrapituitary prolactin is
likely regulated at the level of transcription or translation
and not at the level of release from vacuolar stores.
Interestingly, transcription of prolactin mRNA synthe-
sized in extrapituitary sites is regulated by an alternative
promoter and initiates 5.8 kb upstream of the initiation
site used in lactotrope cells (Gerlo et al. 2006). Although
the alternative initiation site results in inclusion of a novel
exon (exon 1a), the exon is part of the 59 untranslated
region and does not change any amino acids of the encoded
protein (Gerlo et al. 2006). As expected, the extrapituitary
prolactin synthesis is not sensitive to dopamine, and
addition of the dopamine agonist bromocryptine does not
inhibit production of prolactin by cells in culture (Gerlo
et al. 2006). Less is known about the regulatory mecha-
nisms that control expression of prolactin at extrapituitary
sites. In addition, the role played by extrapituitary pro-
lactin during normal physiology is poorly understood.
The prolactin receptor (PRLR) is a 90-kDa protein
consisting of 622 amino acids that belongs to the type I
class of transmembrane receptors. It has a 210-amino-
acid ligand-binding extracellular domain with two type III
fibronectin-like domains and multiple sites for N-linked
glycosylation (Ben-Jonathan et al. 2007). The 364-amino-
acid intracellular domain has no intrinsic kinase activity
or homology with known domains but has a 9-amino-acid
proline-rich region (amino acids 267–275), termed the
Box1 motif. Ligand binding is thought to induce either
dimerization of the receptor or a change in the confor-
mation of a preformed receptor dimer, which activates
the associated cytoplasmic tyrosine kinase Janus kinase
2 (Jak2) (Campbell et al. 1994; Dusanter-Fourt et al. 1994;
Rui et al. 1994; Frank 2002). While Jak2 associates with
the receptor in a prolactin-independent manner, prolactin
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stimulation is required for tyrosine phosphorylation and
activation of Jak2 (DaSilva et al. 1994). Prolactin-dependent
activation of Jak2 induces phosphorylation of the pro-
lactin receptor at multiple tyrosine residues, which
mediates recruitment and activation of signal transducer
and activator of transcription 5 (STAT5a and STAT5b),
STAT1, and STAT3 (David et al. 1994; Gouilleux et al.
1994; Wakao et al. 1994). STAT5a and STAT5b are the
primary effectors of prolactin signaling and are critical for
inducing transcription of genes encoding milk proteins in
mammary epithelial cells. In addition to Jak2, prolactin
also stimulates activation of c-Src, Fyn, and Tec family
tyrosine kinases (Clevenger 2003); mitogen-activated pro-
tein kinase (MAPK); and Akt. While MAPK and Akt are
thought to regulate cell proliferation and cell death path-
ways in response to prolactin stimulation, neither of the
pathways is critical for prolactin-induced milk protein
expression (Clevenger 2003).
Alternative splicing generates multiple prolactin re-
ceptor isoforms that differ in the length of the intracel-
lular domain. In addition to the full-length receptor,
human cells express five different isoforms. One of the
isoforms lacks the transmembrane domain, is secreted
from cells, and may function as a decoy receptor. All of
the isoforms with a short cytoplasmic tail retain the
ability to interact with Jak2 but differ in their ability to
mediate prolactin-induced cell proliferation (Ben-Jonathan
et al. 2007). Rodents have fewer prolactin receptor iso-
forms than humans. In addition to the-full length re-
ceptor, rat cells express two isoforms, and mouse cells
express one (Ben-Jonathan et al. 2007). Isoform expression
varies in a tissue-specific manner and is also differentially
regulated during development and physiological states
such as estrous cycle, pregnancy, and lactation in mice
(Jahn et al. 1991; Nagano and Kelly 1994; Bole-Feysot
et al. 1998). Neither the mechanisms nor the importance
of PRLR isoform switching are well understood. How-
ever, homozygous deletion of the prolactin receptor gene
in mice results in multiple and significant defects in
the reproductive system, including a complete failure to
lactate during first pregnancy (Ormandy et al. 1997), thus
demonstrating a dominant role for prolactin signaling in
reproductive biology.
Autocrine prolactin and mammary gland biology
As discussed above, a role for endocrine prolactin during
mammary gland differentiation is well established. How-
ever, there is reason to believe that autocrine prolactin is
also an important regulator of physiology in mammary
epithelial cells. Transplantation of prolactin/mammary
epithelial cells into mammary fat pads of immunocom-
promised Rag/ hosts resulted in a 2.8-fold decrease in
cell proliferation during lactation, whereas transplanta-
tion of Rag/ mammary epithelium into prolactin/
hosts did not affect proliferation (Naylor et al. 2003),
suggesting that mammary epithelial cells may need
autocrine prolactin during normal physiology. Yet we
do not know whether and how epithelial prolactin is
produced and whether it regulates a prolactin receptor-
mediated signaling pathway by creating an autocrine
loop.
In the October 1, 2012, issue of Genes & Development,
Chen et al. (2012) report on a meticulously performed
study in which they discovered an unexpected role for
autocrine prolactin secreted by mammary epithelial cells
during Akt-induced lactogenic differentiation. Acute tet-
racycline-inducible expression of Akt in MMTV-rtTA;
TetO-Akt1 (MTB/tAkt) transgenicmice promoted STAT5
phosphorylation, formation of lipid droplets, and synthesis
of milk proteins similar to that observed on day 2 of lacta-
tion in wild-type mice. In addition to activating Akt as a
transgene, activation of endogenous Akt by homozygous
loss of PTEN/ also induced expression of milk proteins
and formation of lipid droplets. Furthermore, transplanta-
tion of MTB/tAktmammary epithelial cells into wild-type
mice or in vitro culturing of transgenic mouse-derived
primarymammary epithelial cells also resulted in increased
STAT5 phosphorylation, thus demonstrating that Akt-
induced STAT5 activation is an epithelial cell-intrinsic
phenomenon and does not require paracrine signaling
from the stroma. Expression of MTB/tAkt in STAT5a/b/
mice failed to induce milk protein expression and lacto-
genic differentiation, demonstrating that STAT5a/b activa-
tion is a required step for the Akt-induced lactogenic
differentiation observed in virgin mammary glands.
Expression of Akt in prolactin receptor/ mice failed
to induce STAT5 activation, demonstrating that prolactin
receptor was required for Akt-induced activation of
STAT5. Treatment with conditioned medium (CM) from
MTB/tAkt, MTB/tAkt/STAT5a/5b, or prolactin receptor
transgenic mammary gland-derived cells induced STAT5
phosphorylation in HC11mammary epithelial cells. These
observations raise the possibility of the presence of a
secreted factor induced by MTB/tAKT—independent of
STAT5 and prolactin receptor signaling—that can induce
STAT5 activation. Given the requirement for the pro-
lactin receptor for activation of STAT5, Chen et al. (2012)
observed detectable expression of prolactin in the mam-
mary glands of MTB/tAkt or PTENfl/fl mice. To directly
test whether prolactin is needed for the MTB/tAkt-
induced biology, they crossed MTB/tAkt mice into a
prolactin/ background and demonstrated that MTB/
tAkt-induced prolactin expression is required for the
lactogenic differentiation and milk protein expression
observed in virgin mammary glands.
Interestingly, circulating prolactin levels were not
altered in tetracycline-induced MTB/tAkt mice, and
purified epithelial cell-derived mammary glands expressed
prolactin, suggesting autocrine production of prolactin
by epithelial cells. To directly test whether epithelial
cells make prolactin, the investigators transplanted epi-
thelial cells fromMTB/tAkt/prolactin/ andMTB/tAkt/
prolactin+/+mice into wild-type mammary glands. Mam-
mary outgrowth from MTB/tAkt/prolactin/ epithelial
cells failed to show STAT5 phosphorylation and lacto-
genic differentiation, while the MTB/tAkt/prolactin+/+
cells retained their ability to undergo lactogenic differenti-
ation and phosphorylate STAT5. The lack of differentiation
of prolactin/ cells transplanted into wild-type mice
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demonstrates the inability of endocrine prolactin pro-
duced by the pituitary gland to compensate for the lack of
prolactin gene in the transplanted epithelial cells, thus
demonstrating the requirement for autocrine prolactin
made by epithelial cells.
It is likely that the observations made using transgenic
mice are highly relevant for normal physiology: Trans-
plantation of Atk1//Akt2+/ epithelium into the mam-
mary fat pads of wild-type mice showed decreased milk
protein expression and reduced STAT5 activation,
whereas transplantation of wild-type epithelium into
Atk1//Akt2+/ mammary fat pads induced normal
lactogenic differentiation and STAT5 activation. These
results thus demonstrate the importance of Akt-regulated
autocrine prolactin production inmammary epithelial cells
during normal physiology. This extends a previous study by
the investigators (Chen et al. 2010), which reports that
Akt1//Akt2+/ epithelial cells show up-regulation of
caveolin and SOCS2, negative regulators of the Jak/STAT
signaling pathway. Interestingly, while an increase in
prolactin protein was clearly detected, the prolactin
mRNA was not altered in MTB/tAkt glands, suggesting
that Akt regulates prolactin expression post-transcrip-
tionally. These observations demonstrate a role for Akt-
mediated activation of autocrine prolactin synthesis in
mammary epithelial cells. Akt signaling is an important
regulator of cancer cell growth, survival, and metabo-
lism; thus, the above study raises the possibility of a role
for Akt-regulated autocrine prolactin synthesis in cancer.
Prolactin and breast cancer
A role for prolactin signaling in cancer has long been
recognized. The prolactin receptor is expressed in al-
most all cell types and in 70% of breast cancer samples
(Vonderhaar 1989). Early studies demonstrated that phys-
iological concentrations of prolactin could induce pro-
liferation of primary human breast tumors in organ culture
and tumor-derived primary cells in culture (Welsch et al.
1979; Malarkey et al. 1983). In addition, prolactin induces
proliferation of breast cancer-derived cell lines such as
MCF-7 and T47D under serum-free conditions or in the
presence of charcoal-stripped serum (Biswas and Vonderhaar
1987; Vonderhaar 1999). MCF-7 and T47D breast cancer-
derived cells also synthesize bioactive prolactin in an
autocrine manner (Ginsburg and Vonderhaar 1995), and
prolactin mRNA expression can be detected in primary
human breast cancers (Clevenger et al. 1995). These ob-
servations raise the possibility that cancer cells produce
autocrine prolactin and create an autocrine loop of pro-
lactin/prolactin receptor signaling.
Cell biology
While the most prominent role of prolactin is the regu-
lation of lactogenic differentiation in mammary epithe-
lial cells, the hormone also promotes cell proliferation,
inhibits cell death, and promotes cell migration (Clevenger
2003). The recognition of a prolactin/prolactin receptor
autocrine signaling loop that induces cell proliferation
arose from early studies from the Vonderhaar laboratory
(Ginsburg and Vonderhaar 1995), where they demonstrated
that prolactin-neutralizing antibodies inhibited prolifer-
ation of MCF-7 cells. Furthermore, prolactin induces
expression of cyclin D1 by stimulating Jak2 and STAT5a/b-
mediated transcriptional activation of the cyclin D1 pro-
moter (Schroeder et al. 2002; Brockman and Schuler 2005).
Jak2 is required for both prolactin-induced transcription
of cyclin D1 and retention of cyclin D1 in the nucleus
(Sakamoto et al. 2007). PI 3-kinase enhancer A (PIKE-A)
interacts with prolactin receptor and STAT5 to form a
prolactin receptor/Pike-A/STAT5 protein complex. This
complex is required for prolactin-induced activation of
STAT5 and cyclin D1 expression but is not required for
prolactin-induced activation of Jak2 (Chan et al. 2010). In
addition to Jak2, prolactin stimulation can also activate
Jak1 in a Jak2-independent manner. Down-regulation of
Jak1 interferes with prolactin-induced activation of MAPK
and STAT3 and activation of Jak2, suggesting a role for
Jak1 as an activator of STAT3 and also as an enhancer of
the Jak2–STAT5 pathway (Neilson et al. 2007). Prolactin
can also induce proliferation of mammary epithelial cells
by a Jak2-independent, Src tyrosine kinase-dependentman-
ner, whereby prolactin induces activation of a Src/focal
adhesion kinase/Erk1/2 pathway and also activates the
PI3K pathway to induce expression of cyclin D1 and Myc
to promote cell proliferation (Acosta 2003). In addition
to its effect on mammary epithelial cells, prolactin also
induces proliferation of T lymphocytes and prostate epi-
thelial cells (not discussed here; for a thorough review, see
Clevenger 2003; Ben-Jonathan et al. 2007). Thus, activa-
tion of the prolactin/prolactin receptor signaling pathway
can be a potent mitogenic signal in cancer cells that
express autocrine prolactin.
In addition to promoting cell proliferation, prolactin
can function as a chemoattractant for breast cancer-
derived cell lines (Maus et al. 1999). Prolactin interacts
with and activates the kinase activity of Nek3 (never in
mitosis A-related kinase 3) and promotes an interaction
between the prolactin receptor Nek3 and Vav2, a GTP
exchange factor (Miller 2005), to increase Rac GTP levels
in mammary epithelial cells. Nek3 is required for pro-
lactin-induced actin reorganization and cell motility and
invasion (Miller et al. 2007). In addition, prolactin-stimu-
lated Jak2 kinase phosphorylates the P21-activated kinase
Pak1 (Rider et al. 2007). Active Pak1 induces phosphoryla-
tion of filamin A, an actin-binding protein that promotes
cross-linking of cortical actin filaments to promote mem-
brane ruffling and cell migration (Rider and Diakonova
2011). Interestingly, prolactin receptor expression is asso-
ciated with breast cancer progression, suggesting a likely
relationship between prolactin receptor signaling andmeta-
static progression. However, evidence demonstrating a
critical role for prolactin/prolactin receptor signaling and
metastatic progression in vivo remains to be uncovered.
Rodent models
Consistent with its role in promoting cell proliferation,
prolactin is a well-known regulator of mammary cancer
Autocrine prolactin and its relevance to cancer
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in rodent models (Welsch andNagasawa 1977). Increasing
prolactin levels by daily injections of prolactin increases
the spontaneous incidence of mammary tumors (Boot et al.
1962). In addition, chemical carcinogen-inducedmammary
tumor incidence in different rat strains positively correlates
with concentrations of serum prolactin levels (Boyns et al.
1973). Mammary tumors induced by nitrosomethyl urea
(NMU) secrete autocrine prolactin, and anti-prolactin
antibodies inhibit proliferation in an NMU-induced mam-
mary tumor-derived cell line, suggesting a role for prolactin
as a local mitogen in rat mammary tumors (Mershon et al.
1995). Direct evidence for the ability of prolactin to induce
transformation of mammary epithelial cells in mice comes
from experiments performed using transgenic mice. Ex-
pression of prolactin, but not growth hormone, inmammary
epithelial cells induced development of nonmetastatic,
mammary adenocarcinomas with tubular and squamous
differentiation phenotypes (Wennbo et al. 1997). In addi-
tion, expression of prolactin under the control of neu-
related lipocalin (NRL) promoter—a mammary-selective,
hormonally nonresponsive promoter—induces hyperplastic
growth of the mammary gland by 9 mo of age that prog-
resses to develop ERa+ and ERa mammary tumors of
varying histopathology with signs of invasive behavior
(Rose-Hellekant et al. 2003). Despite their histological
differences, the NRL–prolactin-induced tumors tend to
belong to the estrogen-resistant luminal subtype of breast
cancer (Arendt et al. 2011). Interestingly, overexpression
of prolactin under the control of whey acidic protein
promoter (WAP) does not induce mammary carcinogen-
esis, suggesting that the differentiation state of cells
in which prolactin is overexpressed may influence the
ability of prolactin to induce tumorigenesis (Manhes
2006). In addition to initiating transformation by itself,
prolactin also cooperates with other prominent regulators
of mammary tumorigenesis. Coexpression of NRL–pro-
lactin and an EGF family growth factor, TGFa, signifi-
cantly shortens the development of macrocystic lesions
and adenocarcinomas (Arendt et al. 2006). Together, these
studies highlight an important aspect of prolactin bi-
ology: While prolactin/prolactin receptor signaling pro-
motes lactogenic differentiation of mammary epithelial
cells, aberrant activation of prolactin/prolactin receptor
signaling can transform mammary epithelial cells and
induce mammary tumors.
Human breast cancer
For a long time, it was thought that prolactin’s relation-
ship to cancer is a rodent-specific phenomenon. This
notion has been challenged, and there is now a significant
body of evidence that identifies prolactin as an important
player in human breast cancer. Initial evidence came
from a study involving 424 patients in which women
with more than a median value of serum prolactin showed
a 2.0-fold higher risk of developing breast cancer (Ingram
et al. 1990). A larger case-controlled prospective study as
part of the Nurses’ Health Study (NHS) that included 306
post-menopausal women who were diagnosed with breast
cancer and 448 control subjects demonstrated that women
with high (upper quartile) serum prolactin levels had a
2.0-fold increased risk of developing breast cancer com-
pared with those with low (bottom quartile) serum pro-
lactin levels (Hankinson et al. 1999). A more recent study
involving 377 cases of breast cancer with two controls for
each case, matched for age and menopausal status, also
show a 1.3-fold increase in patients with high (upper
quartile) serum prolactin levels (Tworoger et al. 2007). In
addition to these, there are now multiple studies that
support the positive correlation between high serum
prolactin levels and increased breast cancer risk in both
premenopausal and post-menopausal women (for a re-
view, see Harvey 2011).
As discussed above, dopamine is a key inhibitor of
prolactin secretion from the pituitary gland. Given the
large increase in the use of dopamine antagonists for
treating psychological disorders, it raises the possibility
of the relationship between use of psychotic drugs, serum
prolactin levels, and cancer risk. A large, retrospective
study involving >52,819 patients exposed to dopamine
antagonists and 55,289 not exposed to dopamine antago-
nists demonstrated that use of dopamine antagonists was
associated with a 16% increase in breast cancer with
no effect on the incidence of colon cancer in the same
patient cohort. The patients were tumor-free at the time
they were enrolled in the study, suggesting a positive
relationship with the use of dopamine antagonists and
breast cancer risk (Wang et al. 2002).
In addition to its role during tumor initiation and
progression, prolactin can also augment oncogenic sig-
naling by EGFR and ErbB2/HER2, members of the EGF
family of receptor tyrosine kinases that play important
roles in breast cancer. Prolactin stimulation induces
Erk2-mediated phosphorylation of EGFR and ErbB2
(Huang et al. 2006). In addition, in ErbB2-overexpressing
breast cancer cells, autocrine prolactin-mediated activa-
tion of Jak2 induced tyrosine phosphorylation of ErbB2,
recruitment of Grb2, activation of MAPK, and induction
of cell proliferation. Inhibition of Jak2 decreased pro-
lactin-induced phosphorylation of ErbB2, suggesting a
possible cross-talk between prolactin and ErbB2 signaling
pathways during proliferation of breast cancer cell lines
(Yamauchi 2000). Inhibition of the prolactin receptor using
G129R (prolactin receptor antagonist) inhibits ErbB2 phos-
phorylation, suggesting an opportunity for combination
therapy. Consistent with this possibility, combination of
Herceptin (anti-HER2 therapeutic antibody) and G129R
has an additive effect in inhibiting bothMAPK activation
and growth of BT474 breast cancer cells in cell culture
and in xenograft mouse models (Scotti et al. 2008). Further
studies are needed to explore this novel therapeutic strat-
egy for patients with HER-positive breast cancers that also
express autocrine prolactin.
Recent studies point to a possible role for prolactin
signaling in chemoresistance. Prolactin stimulation induces
expression of the anti-apoptotic protein Bcl-2 in multiple
breast cancer-derived cell lines (Beck et al. 2002), suggesting
a role for prolactin signaling in inhibiting apoptosis. In
addition, prolactin stimulation inhibits cisplatin-induced
cell cycle arrest by activating glutathione-S-transferase,
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a detoxifying enzyme that blocks the ability of cisplatin
to enter the nucleus (LaPensee et al. 2009). Well-conducted
animal studies will be needed to better understand the
role prolactin plays during drug resistance. Furthermore,
it is not clear whether endocrine and autocrine regulation
of prolactin differentially regulate cell death and chemo-
resistance pathways.
Thus, although most of our understanding of prolactin
biology stems from studying its endocrine function, there
is an emerging interest in understanding the regulation of
autocrine prolactin in both normal and cancer epithelia.
Given that most cell types express prolactin receptor,
signals that induce production of autocrine prolactin will
result in activation of an autocrine/paracrine signaling
loop that will impact proliferation, survival, and differ-
entiation of cells. Furthermore, the ability of prolactin to
induce phosphorylation of ErbB2, an oncogenic receptor
tyrosine, raises the possibility that the effect of activating
a prolactin/prolactin receptor autocrine signaling loop
will have implications beyond prolactin signaling and
biology. Last, recognizing the importance of autocrine
prolactin will change the way we consider targeting this
pathway. For example, targeting the prolactin receptor
would be a better choice for therapeutics compared with
using dopamine agonists to inhibit pituitary prolactin
production.
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initiation and provides a direct link between the Akt and Stat5 pathways
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